-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $45

Benzinga·03/30/2026 15:01:09
Listen to the news
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $50 to $45.